| Megan Arthur, MD | |
|
4014 Leavenworth St, Omaha, NE 68105-1053 | |
| (402) 552-7928 | |
| (402) 552-3229 |
| Full Name | Megan Arthur |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 10 Years |
| Location | 4014 Leavenworth St, Omaha, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659786101 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 30832 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Nebraska Medical Center | Omaha, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unmc Physicians | 6002728391 | 1320 |
News Archive
Use of practitioner-led complementary and alternative medicine (CAM), such as acupuncture, massage, osteopathy and chiropractic treatment, rose from 12 per cent of the population in 2005 to 16 per cent of the population in 2015, according to a survey led by researchers at the University of Bristol's Centre for Academic Primary Care.
In order to provide the best medical care for newly diagnosed Parkinson's disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management.
The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 7 days ago
| Entity Name | Unmc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417912114 PECOS PAC ID: 6002728391 Enrollment ID: O20031104000664 |
News Archive
Use of practitioner-led complementary and alternative medicine (CAM), such as acupuncture, massage, osteopathy and chiropractic treatment, rose from 12 per cent of the population in 2005 to 16 per cent of the population in 2015, according to a survey led by researchers at the University of Bristol's Centre for Academic Primary Care.
In order to provide the best medical care for newly diagnosed Parkinson's disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management.
The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Megan Arthur, MD 988102 Nebraska Medical Ctr, Omaha, NE 68198-8102 Ph: () - | Megan Arthur, MD 4014 Leavenworth St, Omaha, NE 68105-1053 Ph: (402) 552-7928 |
News Archive
Use of practitioner-led complementary and alternative medicine (CAM), such as acupuncture, massage, osteopathy and chiropractic treatment, rose from 12 per cent of the population in 2005 to 16 per cent of the population in 2015, according to a survey led by researchers at the University of Bristol's Centre for Academic Primary Care.
In order to provide the best medical care for newly diagnosed Parkinson's disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management.
The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.
Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).
Mayo Clinic today announced plans to establish the Mayo Clinic Proton Beam Therapy Program as part of Mayo's national three-site cancer center in Minnesota, Arizona and Florida. The new program will employ intensity modulated proton therapy — based on pencil beam scanning — which is a more precise form of proton therapy treatment that allows greater control over radiation doses, shorter treatment times and fewer side effects. It is also believed to be more cost effective in selected patients.
› Verified 7 days ago
Dr. Ronald John Sulewski Jr., M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4014 Leavenworth St, Omaha, NE 68105 Phone: 402-552-7928 | |
Tomas Huerta, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 16120 W Dodge Rd, Omaha, NE 68118 Phone: 402-354-0670 Fax: 402-354-0675 | |
Mr. John R Luckasen, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 4242 Farnam St, Ste 360, Omaha, NE 68131 Phone: 402-552-2555 Fax: 402-552-2573 | |
David J Watts, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 909 N 96th St, Suite 201, Omaha, NE 68114 Phone: 402-330-4555 Fax: 402-934-0945 | |
Dr. Sara Elizabeth West, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 909 N 96th St, Suite 201, Omaha, NE 68114 Phone: 402-330-4555 Fax: 402-934-0945 | |
Dr. Scott M Debates, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 515 N 162nd Avennue, Ste. 302, Omaha, NE 68118 Phone: 402-354-0621 Fax: 402-354-0611 | |
Melanie A Ortleb, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 16910 Frances St, Omaha, NE 68130 Phone: 402-505-8777 Fax: 402-933-7767 |